Tisagenlecleucel (Kymriah, Novartis) is indicated for 'paediatric and young adult patients up to and including 25 years of age with B‑cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse'.
The dosage schedule is available in the summary of product characteristics for tisagenlecleucel.
The list price for tisagenlecleucel is £282,000 per infusion (company submission).
The company has a commercial arrangement. This makes tisagenlecleucel available to the NHS with a discount. The size of the discount is commercial in confidence.